Pular para o conteúdo principal
Ranking Invest

PGEN - Precigen, Inc.

Segmento: HealthcarePrecigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Análise Ranking Invest

Valor de Mercado
$ 2.18 Bi
IVR
-0.15Índice proprietário de comparação relativa: -0,15.
IVR2
-0.17Leitura proprietária complementar: -17%.
MLL
-0.17Leitura proprietária complementar: -17%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 43.58 Mi

Dívida Líquida

$ 77.55 Mi

L4T

-$ 157.71 Mi

MM4T

0.60%

Indicadores Básicos

ROE

-361.91%

Índices de Previsibilidade

Receita Líquida

G1.22

Lucro

F4.03

Margem

D0.88

Índices de Tendência

Receita Líquida

D0.56

Lucro

E-3.79

Margem

C2.66

Índices de Endividamento

DIV/PAT

1.78

DIV/L4T

-0.49

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.